Seeking Alpha

More color on Cepheid Q1 results

  • Total top line sales were $106.9M, up 16% yoy. Clinical Systems revenues were $17.3M (+38%) and Clinical Reagents revenues were $83.1M (+24%).
  • The North America business fell slightly (-1%) while the International business grew 56%.
  • Net loss was -$0.13/share compared to breakeven a year ago.
  • 503 GeneXpert systems placed globally.
  • GAAP gross margin was 50% compared to 53% yoy.
  • 2014 guidance range for revenues is $446M - $461M with a loss/share between -$0.38 and -$0.43.
  • (CPHD +0.7%)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|